Anika Therapeutics, Inc.
ANIK· Nasdaq
ANIKAnika Therapeutics, Inc.
Released May 9, 2025, before the open
10-Q filed May 9, 2025, 39 days after period end · 0001171843-25-003019
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $26.17M | $29.02M | $37.92M | $36.69M |
| Net Income | -$4.87M | -$4.51M | -$10.35M | -$2.93M |
| EPS Diluted |
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
| -$0.34 |
| -$0.31 |
| -$0.71 |
| -$0.20 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
